Curt Bradshaw
Keine laufenden Positionen mehr
Karriereverlauf von Curt Bradshaw
Ehemalige bekannte Positionen von Curt Bradshaw
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.11.2019 | 01.11.2020 |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Direktor/Vorstandsmitglied | 01.01.2018 | 01.01.2019 |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 | 01.01.2019 | |
Gründer | 01.01.2018 | 01.01.2019 | |
Präsident | 01.01.2018 | 01.01.2019 | |
Solstice Biologics LLC
Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.01.2012 | 01.01.2018 |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 | 01.01.2018 | |
Gründer | 01.01.2012 | 01.01.2018 | |
Unternehmenssekretär | 01.01.2012 | 01.01.2018 | |
Treasurer | 01.01.2012 | 01.01.2018 | |
Traversa Therapeutics, Inc.
Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Technik-/Wissenschafts-/F&E-Leiter | 21.12.2009 | 19.12.2012 |
NEUBASE THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2020 | - |
LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - | - |
Pfizer Asia | Corporate Officer/Principal | - | - |
Ausbildung von Curt Bradshaw
Texas A&M University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Operativ
Chief Tech/Sci/R&D Officer | 5 |
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ABBOTT LABORATORIES | Health Technology |
LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
NEUBASE THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Solstice Biologics LLC
Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Solstice Biologics LLC develops nucleic acid therapeutics. It specializes in the development of small, cell-permeable RNAi pro-drugs. The company was founded by Steven Dowdy and Curt W. Bradshaw in 2012 and is headquartered in San Diego, CA. | Health Technology |
Traversa Therapeutics, Inc.
Traversa Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. The Company was founded in La Jolla, California in mid-2006, and has secured worldwide exclusive licenses to intellectual property developed during the past five years by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA Interference (RNAi). | Commercial Services |
Pfizer Asia | |
Tallac Therapeutics, Inc.
Tallac Therapeutics, Inc. BiotechnologyHealth Technology Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA. | Health Technology |
- Börse
- Insiders
- Curt Bradshaw
- Erfahrung